JOYZYME GROUP LIMITED
愉悅集團有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

(1) RESIGNATION AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE, THE NOMINATION COMMITTEE AND THE REMUNERATION COMMITTEE; (2) RE-DESIGNATION OF CO-CHAIRMAN AS CHAIRMAN AND CHANGE OF AUTHORISED REPRESENTATIVE; AND (3) CHANGE OF CHIEF EXECUTIVE

The Board announces that with effect from 31 August 2026:

Mr. Tsui Wing Tak has resigned as an independent non-executive director of the Company and ceased to act as the chairman of the audit committee of the Company and a member of the nomination committee of the Company;

Dr. Cheng Faat Ting Gary has been appointed as an independent non-executive director of the Company and the chairman of the audit committee of the Company;

Ms. Zhang Yujing has resigned as Co-Chairman of the Board, the chairman of the nomination committee of the Company and an authorised representative of the Company;

Dr. Zhou Xunyong has been re-designated from a Co-Chairman of the Board to the Chairman of the Board and appointed as the chairman of the nomination committee of the Company, a member of the remuneration committee of the Company and an authorised representative of the Company;

Mr. Zhang Chunguang has resigned as the Chief Executive Officer of the Company and a member of the remuneration committee of the Company;

Mr. Poon Lai Yin Michael has been re-designated from the Chief Financial Officer of the Company to the Chief Executive Officer of the Company; and

Mr. Chau Lai Ki has been re-designated from a Financial Controller of the Company to the Chief Financial Officer of the Company.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Joyzyme Group Limited (the "**Company**", and together with its subsidiaries, the "**Group**") hereby announces that Mr. Tsui Wing Tak ("**Mr. Tsui**") has resigned as an independent non-executive director of the Company ("**INED**") and ceased to act as the chairman of the audit committee of the Company and a member of the nomination committee of the Company with effect from 31 August 2026, as he intended to devote more time to his other personal business and commitments.

Mr. Tsui has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**") or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). The Board would like to express its sincere gratitude for the valuable contribution that Mr. Tsui has made to the Company during his tenure of service.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to further announce that Dr. Cheng Faat Ting Gary ("**Dr. Cheng**") has been appointed as an INED, and the chairman of the audit committee of the Company with effect from 31 August 2026.

Dr. Cheng, aged 58, is a practicing Certified Public Accountant in Hong Kong. He has over 30 years of experiences in financial reporting, business advisory, auditing, accounting, tax investigation and liquidation. From 1996 to 1997, Dr. Cheng had worked at the audit division of the international accounting firm, PricewaterhouseCoopers. In 1998, Dr. Cheng founded his own accounting firm of Gary Cheng & Co and since 2010, he became the managing director of Gary Cheng CPA Limited. Dr. Cheng obtained a Bachelor's degree in Accounting (Honours) and Master's degree of Business Administration from Southern Illinois University, the United States of America (''**USA**''), in 1992 and 1994 respectively, and a Doctor of Business Administration degree from the City University of Hong Kong with research area in ''Independent Non-Executive Director and Corporate Governance'' in 2011. Dr. Cheng is also a Fellow Certified Public Accountant in both Hong Kong and USA and a Certified Tax Advisor of the Taxation Institute of Hong Kong.

Dr. Cheng has been appointed as an independent non-executive director of the Company from September 2020 to July 2025. For public services, Dr. Cheng currently serves as charter president and honorary advisor of the Lions Club of Huaxia Hong Kong. In addition, he is currently a founding and life member of "CityU Eminence Society" as well as a member of the court of the City University of Hong Kong.

Save as disclosed above, Dr. Cheng does not hold any other position in the Company and other members of the Group and any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years before the date of this announcement and he does not have any relationship with any other directors, senior management or substantial or controlling shareholders of the Company.

Dr. Cheng has entered into a letter of appointment with the Company for an initial term of three years commencing from the 31 August 2026 unless and until terminated by either party serving not less than one month's written notice to the other party. Dr. Cheng is entitled to director's emolument of HK$120,000 per annum. Such fee is determined by reference to the Company's remuneration policy and will be subject to review by the remuneration committee of the Company from time to time. Save as disclosed above, Dr. Cheng is not expected to receive any other remuneration for holding his office as an INED.

In accordance with the articles of association of the Company, Dr. Cheng will hold office until the first general meeting of the Company after his appointment and shall then be eligible for re-election. Dr. Cheng will be subject to rotation requirements as contained in the articles of association of the Company and shall retire from office by rotation at least once every three years.

Dr. Cheng does not have any interests in the shares of the Company (the "**Share(s)**") or any of its associated corporations which is required to be disclosed under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Cheng was a director of the following companies, which were incorporated in Hong Kong prior to their respective dissolution and were dissolved by deregistration due to cessation of business:

Name of company	**Date of dissolution**	**Means of dissolution**	**Nature of business**
CYC International (Hong Kong) Limited	9 January 2004	Deregistration under s. 291AA(7) and (9) of the Companies Ordinance (Chapter 32 of the laws of Hong Kong) as in force from time to time before 3 March 2014 (the "**Predecessor Companies Ordinance**")	Trading
Gary Cheng Corporate Services Limited	9 January 2004	Deregistration under s. 291AA(7) and (9) of the Predecessor Companies Ordinance	Dormant
Jobmall Asia Limited	12 March 2010	Deregistration under s. 291AA(7) and (9) of the Predecessor Companies Ordinance	Recruitment business
Worldlion Global Limited	24 February 2017	Deregistration under s. 751 (1) and (3) of the Companies Ordinance (Cap. 622 of the laws of Hong Kong)	Trading
Worldlion Properties Limited	13 July 2012	Deregistration under s. 291AA(7) and (9) of the Predecessor Companies Ordinance	Dormant

Dr. Cheng has confirmed that CYC International (Hong Kong) Limited, Gary Cheng Corporate Services Limited, Jobmall Asia Limited, Worldlion Global Limited and Worldlion Properties Limited were solvent immediately prior to their respective dissolutions. He has further confirmed that there was no wrongful act on his part leading to the above dissolution of the companies and that he is not aware of any actual or potential claim which has been or will be made against him as a result of the dissolution of the above companies.

Dr. Cheng has confirmed that he has met the independence criteria set out in Rule 5.09 of the Rules Governing the Listing of Securities on GEM of the Stock Exchange ("**GEM Listing Rules**"). Save as disclosed above, there are no other matters relating to the appointment of Dr. Cheng that need to be brought to the attention of the Shareholders nor any information that need to be disclosed pursuant to the requirements of Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

The Board would like to express its warmest welcome to Dr. Cheng for joining the Board.

RESIGNATION OF CO-CHAIRMAN

Ms. Zhang Yujing ("**Ms. Zhang**") has resigned as a Co-Chairman of the Board, the chairman of the nomination committee of the Company and an authorised representative of the Company with effect from 31 August 2026. She will remain as an executive Director of the Company.

Ms. Zhang has confirmed that she has no disagreement with the Board and there is no other matter relating to her resignation that needs to be brought to the attention of the Shareholders or the Stock Exchange.

REDESIGNATION TO CHAIRMAN

Dr. Zhou Xunyong ("**Dr. Zhou**"), aged 50, currently an executive Director and a Co-Chairman of the Company, has been redesignated as the Chairman of the Board and appointed as the chairman of the nomination committee of the Company, a member of the remuneration committee of the Company and the authorised representative of the Company with effect from 31 August 2026.

Please refer to the ''Biographies of Directors and Senior Management'' section in the annual report 2025 of the Company dated 27 March 2026 for the biographical details of Dr. Zhou.

RESIGNATION OF CHIEF EXECUTIVE OFFICER

Mr. Zhang Chunguang ("**Mr. Zhang**") intended to devote more time to focus on the management of the business of Shenzhen Huakang Bio-Medical Engineering Limited* (深圳華康生物醫學工程有限公司), which is an indirect wholly-owned subsidiary of our Company, he has resigned as Chief Executive Officer (the "**CEO**") of the Company and a member of the remuneration committee of the Company. He will remain as an executive Director of the Company.

Mr. Zhang has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the Shareholders or the Stock Exchange.

REDESIGNATION OF CHIEF EXECUTIVE OFFICER

Mr. Poon Lai Yin Michael ("**Mr. Poon**"), aged 54, currently an executive Director, the Chief Financial Officer (the "**CFO**"), an Authorised Representative and the Compliance Officer of the Company, has been redesignated as the Chief Executive Officer (the "**CEO**") of the Company. He will remain as an executive Director, an Authorised Representative and the Compliance Officer of the Company and a director of various subsidiaries of the Group.

Please refer to the ''Biographies of Directors and Senior Management'' section in the annual report 2025 of the Company dated 27 March 2026 for the biographical details of Mr. Poon.

REDESIGNATION OF CHIEF FINANCIAL OFFICER

Mr. Chau Lai Ki ("**Mr. Chau**"), aged 43, currently the financial controller and the Company Secretary of the Company, has been redesignated as the CFO. He will remain as the Company Secretary of the Company and a director and a company secretary of various subsidiaries of the Group.

Please refer to the ‘‘Biographies of Directors and Senior Management’’ section in the annual report 2025 of the Company dated 27 March 2026 for the biographical details of Mr. Chau.

“*” is for identification purposes only

By Order of the Board
Joyzyme Group Limited
Dr. Zhou Xunyong
Chairman and Executive Director

Hong Kong, 31 August 2026

As at the date of this announcement, the executive Directors are Dr. Zhou Xunyong, Ms. Zhang Yujing, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; the Non-executive Director is Dr. Bu Su; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Dr. Cheng Faat Ting Gary.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company's website at www.joyzymebiotech.com.